Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3656180 | 0.89 | TSHR (0.62) | TSHRKCNH2IDO1KCNJ1LOXL2 | |
| SCHEMBL4586246 | 0.84 | TSHR (0.56) | TSHRKCNH2IDO1KCNJ1LOXL2 | |
| SCHEMBL4586250 | 0.82 | TSHR (0.65) | TSHRKCNH2IDO1KCNJ1LOXL2 | |
| SCHEMBL8328188 | 0.82 | TSHR (0.55) | TSHRKCNH2IDO1KCNJ1LOXL2 | |
| SCHEMBL7758238 | 0.82 | TSHR (0.55) | TSHRKCNH2IDO1KCNJ1LOXL2 | |
| SCHEMBL7032223 | 0.81 | IDO1 (0.61) | TSHRIDO1LOXL2CYP2C19CYP1A2 | |
| SCHEMBL1165330 | 0.79 | TSHR (0.51) | TSHRKCNH2IDO1KCNJ1LOXL2 | |
| SCHEMBL3192905 | 0.79 | TSHR (0.64) | TSHRKCNH2IDO1KCNJ1LOXL2 | |
| SCHEMBL7931694 | 0.78 | IDO1 (0.53) | TSHRIDO1CYP2C19CYP1A2AKR1C3 | |
| SCHEMBL3292782 | 0.78 | TSHR (0.75) | TSHRKCNH2IDO1KCNJ1LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030181742-A1 | Process for the preparation of pregnane derivatives | KURARAY CO., LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1325928-A1 | PROCESS FOR THE PREPARATION OF PREGNANE DERIVATIVES | Kuraray Co., Ltd. (JP) | 2003-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181742-A1 | Process for the preparation of pregnane derivatives | CYP21A2, CYP11B2, CYP17A1 | TSHR 1634/4885KCNH2 1365/4885IDO1 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.